Mike Clark

8.4k total citations · 3 hit papers
108 papers, 6.3k citations indexed

About

Mike Clark is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology. According to data from OpenAlex, Mike Clark has authored 108 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Radiology, Nuclear Medicine and Imaging, 37 papers in Molecular Biology and 34 papers in Immunology. Recurrent topics in Mike Clark's work include Monoclonal and Polyclonal Antibodies Research (58 papers), Glycosylation and Glycoproteins Research (24 papers) and T-cell and B-cell Immunology (18 papers). Mike Clark is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (58 papers), Glycosylation and Glycoproteins Research (24 papers) and T-cell and B-cell Immunology (18 papers). Mike Clark collaborates with scholars based in United Kingdom, United States and South Sudan. Mike Clark's co-authors include Herman Waldmann, Lutz Riechmann, Greg Winter, G Hale, Stephen Cobbold, Kathryn L. Armour, C Bindon, M. Brüggemann, Martin J.S. Dyer and Julia M. Phillips and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Mike Clark

107 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reshaping human antibodies for therapy

1988 1.2k citations Lutz Riechmann, Mike Clark et al. Nature profile →
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1988 550 citations G Hale, Mike Clark et al. The Lancet profile →
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

1987 501 citations M. Brüggemann, Gareth T. Williams et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mike Clark United Kingdom	37	3.1k	2.5k	2.1k	949	641	108	6.3k
Lucien A. Aarden Netherlands	45	1.6k 0.5×	4.4k 1.8×	2.4k 1.1×	1.2k 1.3×	570 0.9×	101	9.1k
Heddy Zola Australia	42	1.2k 0.4×	2.6k 1.1×	1.8k 0.8×	737 0.8×	559 0.9×	259	6.3k
L Aarden Netherlands	47	1.7k 0.6×	4.1k 1.6×	1.8k 0.8×	1.4k 1.5×	470 0.7×	104	8.3k
Edna Mozes Israel	44	1.9k 0.6×	3.9k 1.6×	1.3k 0.6×	496 0.5×	465 0.7×	271	6.5k
René R. P. de Vries Netherlands	51	1.5k 0.5×	3.3k 1.3×	823 0.4×	561 0.6×	1.1k 1.7×	138	7.3k
Alfred D. Steinberg United States	59	2.7k 0.9×	5.8k 2.3×	1.5k 0.7×	811 0.9×	934 1.5×	234	11.2k
Leendert A. Trouw Netherlands	55	2.7k 0.9×	4.7k 1.9×	1.5k 0.7×	511 0.5×	324 0.5×	218	9.8k
Thomas M. Chused United States	47	1.1k 0.4×	3.3k 1.3×	1.5k 0.7×	537 0.6×	655 1.0×	111	6.0k
Robert I. Fox United States	48	2.3k 0.7×	3.1k 1.2×	1.7k 0.8×	1.5k 1.6×	1.2k 1.9×	137	12.6k
Alain Bernard France	51	929 0.3×	2.5k 1.0×	2.5k 1.2×	1.3k 1.4×	306 0.5×	220	8.3k

Countries citing papers authored by Mike Clark

Since Specialization

Citations

This map shows the geographic impact of Mike Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Clark more than expected).

Fields of papers citing papers by Mike Clark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Clark. The network helps show where Mike Clark may publish in the future.

Co-authorship network of co-authors of Mike Clark

This figure shows the co-authorship network connecting the top 25 collaborators of Mike Clark. A scholar is included among the top collaborators of Mike Clark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike Clark. Mike Clark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stapleton, Nigel M., Maximilian Brinkhaus, Kathryn L. Armour, et al.. (2019). Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge. Scientific Reports. 9(1). 7363–7363. 26 indexed citations

Stapleton, Nigel M., Sylvia Armstrong‐Fisher, Jan Terje Andersen, et al.. (2018). Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport. Molecular Immunology. 95. 1–9. 16 indexed citations

Armour, Kathryn L., et al.. (2014). Clearance of Human IgG1-Sensitised Red Blood Cells In Vivo in Humans Relates to the In Vitro Properties of Antibodies from Alternative Cell Lines. PLoS ONE. 9(10). e109463–e109463. 1 indexed citations

Sack, Coralynn, Véronique Phan, Rachel Grafton, et al.. (2011). A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. Journal of Crohn s and Colitis. 6(3). 302–310. 88 indexed citations

Ghevaert, Cédric, David A. Wilcox, Juan Fang, et al.. (2008). Developing recombinant HPA-1a–specific antibodies with abrogated Fcγ receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. Journal of Clinical Investigation. 118(8). 2929–38. 27 indexed citations

Kirton, Christopher M., Marja‐Leena Laukkanen, Craig Stolen, et al.. (2005). Function-blocking antibodies to human vascular adhesion protein-1: A potential anti-inflammatory therapy. European Journal of Immunology. 35(11). 3119–3130. 23 indexed citations

Armour, Kathryn L., Jan G. J. van de Winkel, Lorna M. Williamson, & Mike Clark. (2003). Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies. Molecular Immunology. 40(9). 585–593. 59 indexed citations

Clark, Mike, et al.. (2000). Antibody humanization: a case of the ‘Emperor’s new clothes’?. Immunology Today. 21(8). 397–402. 201 indexed citations

Clark, Mike, et al.. (1996). A novel complex, p40/42, is constitutively associated with the B cell antigen receptor and phosphorylated upon receptor stimulation. The Journal of Immunology. 157(9). 3828–3837. 3 indexed citations

10.

Gast, G C de, Anja A. van Houten, Inez-Anne Haagen, et al.. (1995). Clinical Experience with CD3 X CD19 Bispecific Antibodies in Patients with B Cell Malignancies. Journal of Hematotherapy. 4(5). 433–437. 55 indexed citations

11.

Gast, Gijsbert C. de, Inez-Anne Haagen, Anja A. van Houten, et al.. (1995). CD8 T cell activation after intravenous administration of CD3×CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunology Immunotherapy. 40(6). 390–396. 40 indexed citations

12.

Haagen, Inez-Anne, et al.. (1994). Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunology Immunotherapy. 39(6). 391–396. 19 indexed citations

13.

Isaacs, John D., Mike Clark, Judith Greenwood, & Herman Waldmann. (1992). Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. The Journal of Immunology. 148(10). 3062–3071. 57 indexed citations

14.

Gorman, Scott D. & Mike Clark. (1990). Humanisation of monoclonal antibodies for therapy.. PubMed. 2(6). 457–66. 33 indexed citations

15.

Clark, Mike & Herman Waldmann. (1989). THERAPY WITH HYBRID ANTIBODIES. British Journal of Cancer. 59(1). 304–304. 3 indexed citations

16.

Riechmann, Lutz, Mike Clark, Herman Waldmann, & Greg Winter. (1988). Reshaping human antibodies for therapy. Nature. 332(6162). 323–327. 1176 indexed citations breakdown →

17.

Hale, G, Mike Clark, Greg Winter, et al.. (1988). REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H. The Lancet. 332(8625). 1394–1399. 550 indexed citations breakdown →

18.

Brüggemann, M., Gareth T. Williams, C Bindon, et al.. (1987). Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.. The Journal of Experimental Medicine. 166(5). 1351–1361. 501 indexed citations breakdown →

19.

Benjamin, Reuben, Stephen Cobbold, Mike Clark, & Herman Waldmann. (1986). Tolerance to rat monoclonal antibodies. Implications for serotherapy.. The Journal of Experimental Medicine. 163(6). 1539–1552. 124 indexed citations

20.

Hale, G, Mike Clark, & Herman Waldmann. (1985). Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes.. The Journal of Immunology. 134(5). 3056–3061. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact